Medicine Description uptravi 1000 mcg
UPTRAVI Tablets are indicated for the treatment of chronic pulmonary arterial hypertension (PAH) and help reduce the
risk of serious disease-related complications. The active ingredient acts as a selective prostacyclin receptor
agonist, promoting relaxation and dilation of the blood vessels within the lungs.
This mechanism helps lower pulmonary vascular resistance, allowing blood to flow more easily and reducing the workload
on the right side of the heart. Consistent use of the medication may improve exercise capacity, enabling patients to
perform daily activities and walk longer distances with less fatigue.
UPTRAVI Ingredients
Selexipag.
UPTRAVI Strengths
Film-coated tablets, 200 mcg, pack of 140 tablets.
Film-coated tablets, 200 mcg, pack of 60 tablets.
Film-coated tablets, 400 mcg, pack of 60 tablets.
Film-coated tablets, 600 mcg, pack of 60 tablets.
Film-coated tablets, 800 mcg, pack of 60 tablets.
Film-coated tablets, 1000 mcg, pack of 60 tablets.
Film-coated tablets, 1200 mcg, pack of 60 tablets.
Film-coated tablets, 1400 mcg, pack of 60 tablets.
Film-coated tablets, 1600 mcg, pack of 60 tablets.
Uses of UPTRAVI
-
Long-term treatment of pulmonary arterial hypertension to improve exercise capacity and walking distance.
-
Helps reduce the risk of disease progression and serious cardiovascular and pulmonary vascular complications.
-
Lowers the likelihood of hospitalization due to worsening respiratory function or right-sided heart failure.
UPTRAVI Dosage
The recommended starting dose is 200 mcg taken twice daily, once in the morning and once in the evening, at regular
intervals. The dose is usually increased by 200 mcg twice daily each week until the optimal maintenance dose is
reached, based on the patient's tolerance and clinical response.
The maximum recommended maintenance dose is 1600 mcg twice daily, as determined by the treating physician.
Side Effects of UPTRAVI
Mild to moderate headache.
Temporary facial flushing.
Gastrointestinal disturbances.
Pain in the jaw, muscles, bones, or joints.
Contraindications of UPTRAVI
Do not use this medication if you have a known hypersensitivity to selexipag or any of the inactive ingredients in the
formulation.
Concurrent use with strong CYP2C8 inhibitors, such as gemfibrozil, is contraindicated because it can markedly increase
blood levels of selexipag and raise the risk of adverse effects.
The medication is also contraindicated in patients with severe hepatic impairment or those with a recent history of
acute myocardial infarction or unstable stroke, unless otherwise determined by a specialist.
UPTRAVI Alternatives
Ventovis.
Revatio.
Tracleer.
Use During Pregnancy and Breastfeeding
The use of this medication during pregnancy should generally be avoided unless the expected benefit to the mother
outweighs the potential risk to the fetus, as determined by the treating physician.
Breastfeeding is not recommended during treatment because there are insufficient data regarding the excretion of
selexipag into human breast milk or its safety for nursing infants.
Storage Conditions
Store in a dry place at room temperature, away from moisture and direct sunlight.
Do not store at temperatures above 30°C.
Keep the medication in its original package and out of the reach of children.